Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

12

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and...

30

TriSalus Life Sciences Announces $22.0 Million Private Placement and Preliminary Q1 2025 Unaudited Financial Results

Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated...

4

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the...

3

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the...

12

TriSalus Presents Additional Data for SD-101 Delivered by Proprietary PEDD™ Method with TriNav™ Device for Uveal Melanoma Liver Metastases at ASCO Annual Meeting

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the...

20

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

DENVER and FORT LAUDERDALE, Fla., April 20, 2023 – TriSalus Life Sciences® Inc., (“TriSalus” or the “Company”),...

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes...

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

Studies evaluating methods to overcome two major challenges in treating patients with liver and...

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

Data further substantiates potential to significantly improve immunotherapy outcomes for patients with liver and...

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver...

6

TriSalus Life Sciences Appoints Sean Murphy to Board of Directors

Industry expert brings decades of experience commercializing biopharmaceutical, medical device and diagnostic products DENVER,...

Recent developments

News

May

12

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

April

30

TriSalus Life Sciences Announces $22.0 Million Private Placement and Preliminary Q1 2025 Unaudited Financial Results

November

4

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

November

3

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

June

12

TriSalus Presents Additional Data for SD-101 Delivered by Proprietary PEDD™ Method with TriNav™ Device for Uveal Melanoma Liver Metastases at ASCO Annual Meeting

April

20

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

February

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

December

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

November

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

April

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

October

6

TriSalus Life Sciences Appoints Sean Murphy to Board of Directors